Nuvectis Pharma, Inc.: valuation

NVCTNASDAQHealthcare · Pharmaceutical Preparations

Price

$19.39

November 20, 2026Market cap $667M

What Ploutos Investor adds for Nuvectis Pharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 5 fiscal years, from 2021
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Valuation today

What the market pays for the company's earnings, cash flow, book value and revenue at $19.39 (November 20, 2026), beside the median of its past fiscal years.

Today's P/B (5.3) is 57% below the median of the chart's 3 years (12.1).

EV / EBIT
–
EV / Revenue
–
Earnings yield
–
FCF yield
–
Market cap
$667M
enterprise value $526M
  • 2025
    P/E–
  • 2024
    P/E–
  • 2023
    P/E–

Each multiple at the closing price of the fiscal year's last trading day and the same year's figures. A year with a loss or negative free cash flow has no P/E or P/FCF.

Valuation against its own past

NVCT's P/E, P/FCF and P/B at each year-end price, from 2021 to 2022, 2 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

DCF calculator

What is Nuvectis Pharma worth on your own assumptions?

The DCF calculator opens with the company's figures already filled in from its filings. You set how fast its cash flow grows and the return you ask for, and see the value those assumptions give.

Free cash flow, 12 months
-$40M
Net cash
–
Shares
34.39M
FCF, 5-year average a year
–
Revenue, 5-year average a year
–
Price
$19.39

The full analysis

What do Nuvectis Pharma's filings show?

The multiples say what the market pays for Nuvectis Pharma. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about NVCT's valuation

Didn't find what you were looking for?

Ask us
How do I work out what NVCT is worth?

With the DCF calculator: it opens with Nuvectis Pharma's figures from its filings, you enter your assumptions for growth and the return you ask for, and see the value they give. The company pages give no price target of their own. A full analysis gives a fair-value range, which is an estimate, not a target.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. The estimated fair value, where shown, is our estimate, labelled as one: not a fact, not a score and not a recommendation to buy or sell.